目的：研究肿瘤标志物癌胚抗Ô（CEA）、人鳞状细胞癌相关抗Ô（SCCAg）、神经元特异性烯醇化酶（NSE）在非小细胞肺癌晚期、过程中对疗效评价的临床应用价值。方法：78例晚期非小细胞肺癌为研究对象，根据患者靶向药物治疗后不同疗效分为部分缓解组39例、稳定病变组24例、进展组15例，比较三组研究对象靶向药物治疗前与治疗八周后肿瘤标志物CEA、SCCAg、NSE血清水平的变化情况，探讨肿瘤标志物疗效评价的临床应用价值。结果：不同病理类型非小细胞肺癌肿瘤标志物比较：CEA在鳞癌、鳞腺癌、腺癌中依次升高任意组间均有统计学差异；SCCAg在腺癌、鳞腺癌、鳞癌中依次升高任意组间均有统计学差异；NSE在腺癌最高，在鳞癌、鳞腺癌中无统计学差异；部分缓解组非小细胞癌患者肿瘤标志物CEA、SCCAg、NSE血清水平均出现下降，差异有统计学意义；稳定病变组非小细胞癌患者肿瘤标志物CEA、SCCAg、NSE血清水平无明显变化；进展组部分缓解组非小细胞癌患者肿瘤标志物CEA、SCCAg、NSE血清水平均出现升高，差异有统计学意义。结论：肿瘤标志物的监测为了解分子靶向治疗效果的一个可靠途径，也是分子靶向治疗药物选择的依据。

 Objective To study the tumor markers carcinoembryonic antigen (CEA) and squamous cell carcinoma associated antigen (SCCAg), neuron specific enolase (NSE) in advanced non-small cell lung cancer, in the process of evaluation of the efficacy of clinical application. Methods 78 cases of advanced non-small cell lung cancer patients as the research object, according to the targeted therapy after curative effect is divided into partial remission group 39 cases, 24 cases of stable disease group, 15 cases in group, compared three groups of subjects targeted drug therapy before and after eight weeks of treatment, tumor markers CEA, SCCAg and NSE in serum the level changes of tumor markers in evaluating the therapeutic effect of clinical application. Results The results of different pathological types of non-small cell lung cancer tumor markers: CEA increased statistically in any group of squamous cell carcinoma, squamous adenocarcinoma and adenocarcinoma; SCCAg increased and there was significant difference in any group in adenocarcinoma, squamous adenocarcinoma, squamous cell carcinoma; NSE is the highest in adenocarcinoma, no statistically significant difference in squamous cell carcinoma, squamous adenocarcinoma; partial remission group of patients with non-small cell lung cancer tumor markers CEA, SCCAg, NSE serum levels were decreased, the difference was statistically significant; stable disease group non-small cell cancer tumor markers CEA, SCCAg and NSE serum levels no significant change; partial remission in patients with tumor progression of non-small cell carcinoma markers CEA, SCCAg, NSE serum levels were elevated, the difference was statistically significant. Conclusion The monitoring of tumor markers is a reliable approach to understand the effectiveness of molecular targeted therapies, and is also the basis for molecular targeted drug selection.